» Articles » PMID: 35632578

Evaluation of the Real-World Effectiveness of Vaccines Against COVID-19 at a Local Level: Protocol for a Test-Negative Case-Control Study

Overview
Date 2022 May 28
PMID 35632578
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccines against COVID-19 approved for use in the EU/EEA have been shown to be highly effective against wild-type SARS-CoV-2. However, their effectiveness against new variants may be reduced. This study aims to evaluate the effectiveness of vaccines against COVID-19 in the prevention of symptomatic and severe disease, during pre- and post-omicron phases. Individuals who sought treatment at the emergency department of a Portuguese hospital with COVID-19-like disease and were tested for SARS-CoV-2 are the subjects of the study. Patients who received a positive result are considered cases, while those with negative results are the controls. The test-negative case-control method is one of the study designs recommended by WHO to estimate the effectiveness of vaccines against COVID-19. The main advantage of this design is that it controls for the healthcare seeking bias, commonly present in traditional cohort and case-control designs. This study may have broad implications for understanding the real-world performance of the COVID-19 vaccines at the local level, which may play a key role in promoting adherence to vaccination. Moreover, this study may contribute to inform decisions regarding booster doses and variant-specific vaccine formulations leading to the control of this and future pandemics.

Citing Articles

Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges-A Narrative Review.

Hodel K, Sampaio Dotto Fiuza B, Conceicao R, Aleluia A, Pitanga T, Moraes Dos Santos Fonseca L Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931474 PMC: 11206969. DOI: 10.3390/ph17060807.


COVID-19 vaccines effectiveness against symptomatic disease and severe outcomes, 2021-2022: a test-negative case-control study.

Brazete C, Brazete J, Alves F, Aguiar A, Goncalves A, Cardoso M Public Health. 2023; 218:84-91.

PMID: 36989570 PMC: 9943732. DOI: 10.1016/j.puhe.2023.02.015.


Evaluating Data Sharing of SARS-CoV-2 Genomes for Molecular Epidemiology across the COVID-19 Pandemic.

Rito T, Fernandes P, Duarte R, Soares P Viruses. 2023; 15(2).

PMID: 36851774 PMC: 9959893. DOI: 10.3390/v15020560.

References
1.
French J, Deshpande S, Evans W, Obregon R . Key Guidelines in Developing a Pre-Emptive COVID-19 Vaccination Uptake Promotion Strategy. Int J Environ Res Public Health. 2020; 17(16). PMC: 7459701. DOI: 10.3390/ijerph17165893. View

2.
Cohen A, Taylor Jr T, Farley M, Schaffner W, Lesher L, Gershman K . An assessment of the screening method to evaluate vaccine effectiveness: the case of 7-valent pneumococcal conjugate vaccine in the United States. PLoS One. 2012; 7(8):e41785. PMC: 3411566. DOI: 10.1371/journal.pone.0041785. View

3.
Shiehzadegan S, Alaghemand N, Fox M, Venketaraman V . Analysis of the Delta Variant B.1.617.2 COVID-19. Clin Pract. 2021; 11(4):778-784. PMC: 8544471. DOI: 10.3390/clinpract11040093. View

4.
Cele S, Jackson L, Khoury D, Khan K, Moyo-Gwete T, Tegally H . Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022; 602(7898):654-656. PMC: 8866126. DOI: 10.1038/s41586-021-04387-1. View

5.
Chung H, He S, Nasreen S, Sundaram M, Buchan S, Wilson S . Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ. 2021; 374:n1943. PMC: 8377789. DOI: 10.1136/bmj.n1943. View